Immunome Inc (IMNM)
12.96
+0.14
(+1.09%)
USD |
NASDAQ |
Nov 05, 16:00
12.96
0.00 (0.00%)
After-Hours: 16:20
Immunome Enterprise Value: 491.54M for Nov. 4, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 04, 2024 | 491.54M |
| November 01, 2024 | 417.68M |
| October 31, 2024 | 410.47M |
| October 30, 2024 | 454.31M |
| October 29, 2024 | 454.31M |
| October 28, 2024 | 468.12M |
| October 25, 2024 | 448.91M |
| October 24, 2024 | 442.90M |
| October 23, 2024 | 418.28M |
| October 22, 2024 | 424.88M |
| October 21, 2024 | 436.89M |
| October 18, 2024 | 459.12M |
| October 17, 2024 | 447.70M |
| October 16, 2024 | 462.72M |
| October 15, 2024 | 453.11M |
| October 14, 2024 | 451.31M |
| October 11, 2024 | 456.11M |
| October 10, 2024 | 434.49M |
| October 09, 2024 | 460.32M |
| October 08, 2024 | 496.35M |
| October 07, 2024 | 469.32M |
| October 04, 2024 | 512.56M |
| October 03, 2024 | 528.18M |
| October 02, 2024 | 532.38M |
| October 01, 2024 | 533.58M |
| Date | Value |
|---|---|
| September 30, 2024 | 599.64M |
| September 27, 2024 | 585.23M |
| September 26, 2024 | 582.83M |
| September 25, 2024 | 578.02M |
| September 24, 2024 | 599.04M |
| September 23, 2024 | 562.41M |
| September 20, 2024 | 621.86M |
| September 19, 2024 | 639.88M |
| September 18, 2024 | 652.49M |
| September 17, 2024 | 646.48M |
| September 16, 2024 | 669.91M |
| September 13, 2024 | 680.72M |
| September 12, 2024 | 605.05M |
| September 11, 2024 | 590.03M |
| September 10, 2024 | 600.24M |
| September 09, 2024 | 599.64M |
| September 06, 2024 | 534.78M |
| September 05, 2024 | 575.62M |
| September 04, 2024 | 605.05M |
| September 03, 2024 | 564.81M |
| August 30, 2024 | 633.27M |
| August 29, 2024 | 636.88M |
| August 28, 2024 | 654.29M |
| August 27, 2024 | 620.66M |
| August 26, 2024 | 665.10M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
-15.71M
Minimum
May 13 2022
1.421B
Maximum
Mar 07 2024
221.76M
Average
118.61M
Median
Sep 03 2021
Enterprise Value Benchmarks
| CEL-SCI Corp | 50.50M |
| AIM ImmunoTech Inc | 8.843M |
| IGC Pharma Inc | 26.81M |
| NovaBay Pharmaceuticals Inc | 3.645M |
| Protalix BioTherapeutics Inc | 69.53M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -36.12M |
| Revenue (Quarterly) | 2.364M |
| Total Expenses (Quarterly) | 36.06M |
| EPS Diluted (Quarterly) | -0.60 |
| Profit Margin (Quarterly) | -1.53K% |
| Earnings Yield | -120.8% |
| Normalized Earnings Yield | -36.16 |